Market Intelligence

Amid “significant uncertainty” for the off-patent industry caused by the war in Iran, the IGBA has warned that a prolonged conflict “could make solvent supply a critical concern” while escalating costs and squeezed margins could affect the long-term sustainability of affordable medicines.

Merck, Johnson & Johnson, AstraZeneca and Roche are among the big pharma manufacturers that will face substantial exclusivity losses in the US this year.

With concerns building over the potential impact on medicines supply of the war in Iran, Medicines for Europe and Medicines UK have offered a measured assessment of current supply-chain pressures and the potential for future disruption.

A host of unusually high price increases for UK generics in February led the Department of Health and Social Care to issue the highest number of price concessions seen in almost three years.

As the US biosimilars market continues to evolve, Cardinal Health’s director of biosimilars Dracey Poore talks to Generics Bulletin for an exclusive Q&A.

At the AAM’s Access! 2026 conference, a dedicated panel on the latest developments for biosimilars discussed challenges and opportunities in the US market, predicting consolidation among current players as well as calling for policies that put biosimilars first.

The UK generics market kicked off the new year with huge triple-digit average price rises for a host of products. Market researcher WaveData reveals the details.

As India implements minimum import prices for certain antibiotics and key starting materials, Sandoz's Simon Goeller speaks to Generics Bulletin about the potential for Chinese suppliers to dominate the world market and weaponize supply.

In a busy month for triple-digit percentage average price rises for generics in the UK, repaglinide led the pack in December.

The US ranibizumab market has seen more than its fair share of ups and downs, with the latest developments vastly reducing biosimilar penetration and allowing Lucentis to recapture around 90% of the market. Generics Bulletin looks at the reasons why.

Propranolol prices that were almost five times higher in November meant that the beta-blocker topped our table of UK price rises this month, as ciprofloxacin prices also continued to climb.

When it comes to predicting the future for generic GLP-1s, Sandoz CEO Richard Saynor believes that “everyone’s asking the wrong questions,” pointing to the importance of manufacturing capacity and ability to supply the, rather than the potential market size, as the key factor.

Thanks to a late surge in pricing in October, ciprofloxacin 500mg tablets had the fastest-rising generic price in the UK last month, according to the latest figures from WaveData.

Sandoz’s CEO used the firm’s latest results call to highlight “trade distortion” in the pencillins market as a result of US tariffs, urging European authorities to take action to reduce the region’s “geopolitical exposure” and safeguard the long-term sustainability of European-produced penicillins.

Building on increases seen in August, UK price rises continued to be seen across multiple presentations of olanzapine in September, according to the latest figures from WaveData.

A massive 1,115% average price increase was seen for indapamide 2.5mg tablets in the UK in August.

An executive order has given the go-ahead for US tariffs on Japan to be amended to “zero percent” for generics, just weeks after the EU revealed an effective exemption from its own US tariffs. Meanwhile, a separate order suggests that generics could enjoy broader global exemptions from tariffs.

In its latest savings report, the AAM calculates that using generics and biosimilars saved the US around $467bn in 2024, with more than $20bn of this figure coming from biosimilars.

High-strength ibuprofen tablets saw the largest average price increase of all UK generics in July, according to the latest figures from WaveData.

This article compiles all of the data from Generics Bulletin’s 2025 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.